Did Unequal Follow-Up Times Make Two PAH Survival Percentages Directly Comparable?
Two survival percentages should not be read as though they were measured at one common follow-up time when the observation periods differ. Uhland and colleagues compared treatment response and survival in 64 patients with methamphetamine-associated pulmonary arterial hypertension, or Meth-PAH, and 74 with idiopathic PAH in a single-center prospective cohort.
What did the abstract compare?
The abstract reports transplant-free survival of 54 of 64 patients, or 84.4%, in Meth-PAH over a mean follow-up of 46 months. It reports 54 of 74, or 72.9%, in idiopathic PAH over a mean follow-up of 67 months.
Those reported proportions do not by themselves establish that one group had better survival at a fixed time such as five years. One group was observed for a longer average period. The time at risk and the handling of incomplete follow-up matter to the comparison.
Why the time-to-event analysis matters
The investigators used Kaplan–Meier and Cox regression analyses starting at diagnostic catheterization, with right censoring at the last confirmed communication. The age- and sex-adjusted hazard ratio for Meth-PAH was 0.731, with a reported 95% confidence interval from 0.349 to 1.530. The association was not statistically significant.
That interval is compatible with substantially different hazard estimates. A nonsignificant comparison does not prove exact equivalence, and the raw abstract percentages should not replace the analysis of time and censoring. The authors also acknowledge incomplete longitudinal data and unequal censoring.
What the care setting contributes
The program used specialist, nursing and psychological support to evaluate patients for therapy, including parenteral subcutaneous prostacyclin when indicated. This was not a randomized comparison assigning otherwise interchangeable patients to methamphetamine exposure or no exposure, or to one uniform treatment.
The findings describe outcomes in that care setting. They do not establish that continued drug use is harmless, that all programs will obtain the same results or that the reported group outcomes predict an individual patient’s course.
The useful conclusion is that meaningful treatment response was observed in Meth-PAH within this cohort. Interpretation of comparative survival still requires the actual follow-up periods, censoring rules and uncertainty rather than a direct subtraction of two percentages.
Source: Uhland C, Gibbs A, Insel M, Kubba S, Rischard FP. Treatment Response and Survival in Methamphetamine-Associated Pulmonary Arterial Hypertension. Journal of the American Heart Association. 2025;14:e042673. doi:10.1161/JAHA.125.042673.



